Elsaie Mohamed L, Ibrahim Shady M
a Department of Dermatology , National Research Center , Cairo , Egypt.
b Al-Azhar University , Cairo , Egypt.
J Cosmet Laser Ther. 2018 Jun;20(3):152-155. doi: 10.1080/14764172.2017.1343951. Epub 2018 Mar 9.
Cutaneous leishmaniasis is a prevalent skin condition especially in the Middle Eastern region. The use of pulsed dye laser (PDL) for the treatment of cutaneous leishmaniasis (CL) has not been thoroughly evaluated. We assessed primarily the efficacy of 595-nm PDL in the treatment of CL lesions and interpreted its impact on the quality of life (QOL) of affected patients as measured by the Dermatology Life Quality Index (DLQI).
Twenty-five lesions from 12 patients were treated with a single pass of PDL over the whole lesions to develop a purpuric end point. Parameters used for this treatment were 7 J/cm fluence, 10-mm spot size, and 0.45-ms pulse duration. The laser settings were maintained in all subsequent treatments.
Excellent response was noted in 13 of the 25 lesions after 3 sessions, while 12 of the remaining 25 lesions required 4 sessions toward complete recovery. The mean DLQI scores pre- and post-laser treatments were 12.67 and 4.25, respectively. All patients experienced a statistically significant improvement in their QOL (p < 0.05, paired t-test).
The PDL is a new safe modality for treating cases of CL with further larger-scale studies could better determine its role.
皮肤利什曼病是一种常见的皮肤疾病，尤其在中东地区。脉冲染料激光（PDL）用于治疗皮肤利什曼病（CL）尚未得到充分评估。我们主要评估了595纳米PDL治疗CL皮损的疗效，并通过皮肤病生活质量指数（DLQI）来解读其对受影响患者生活质量（QOL）的影响。
对12例患者的25处皮损进行单次PDL治疗，直至出现紫癜终点。该治疗使用的参数为能量密度7 J/cm、光斑大小10毫米、脉冲持续时间0.45毫秒。在所有后续治疗中保持激光设置不变。
25处皮损中有13处在3次治疗后反应良好，其余25处皮损中有12处需要4次治疗才能完全恢复。激光治疗前后的平均DLQI评分分别为12.67和4.25。所有患者的生活质量均有统计学意义的改善（p < 0.05，配对t检验）。
PDL是治疗CL病例的一种新的安全方法，进一步的大规模研究可以更好地确定其作用。
